These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19738567)

  • 21. Neuropharmacological treatment of mental dysfunction in Parkinson's disease.
    McNamara P; Durso R
    Behav Neurol; 2006; 17(1):43-51. PubMed ID: 16720959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease.
    Rosqvist K; Odin P; Hagell P; Iwarsson S; Nilsson MH; Storch A
    J Parkinsons Dis; 2018; 8(3):409-420. PubMed ID: 30056433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [An impact of pronoran on cognitive and affective disorders in Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):41-7. PubMed ID: 15875942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
    Hanna-Pladdy B; Pahwa R; Lyons KE
    J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor.
    Tarsy D; Scollins L; Corapi K; O'Herron S; Apetauerova D; Norregaard T
    Stereotact Funct Neurosurg; 2005; 83(5-6):222-7. PubMed ID: 16534254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mirapex (pramipexole) in the treatment of non-motor disturbances in Parkinson's disease].
    Nodel' MR; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(5):32-8. PubMed ID: 18577955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classics in Chemical Neuroscience: Pramipexole.
    Wilson SM; Wurst MG; Whatley MF; Daniels RN
    ACS Chem Neurosci; 2020 Sep; 11(17):2506-2512. PubMed ID: 32786316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease.
    Solla P; Cannas A; Ibba FC; Loi F; Corona M; Orofino G; Marrosu MG; Marrosu F
    J Neurol Sci; 2012 Dec; 323(1-2):33-9. PubMed ID: 22935408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
    Navan P; Findley LJ; Undy MB; Pearce RK; Bain PG
    Eur J Neurol; 2005 Jan; 12(1):1-8. PubMed ID: 15613140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
    Relja M; Klepac N
    J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole].
    Letvinenko IV; Odinak MM; Mogil'naia VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(11):36-8. PubMed ID: 19008798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate.
    Drijgers RL; Verhey FR; Tissingh G; van Domburg PH; Aalten P; Leentjens AF
    J Neurol Sci; 2012 Sep; 320(1-2):121-6. PubMed ID: 22824349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of pramipexole on depressive symptoms in Parkinson's disease.
    Yasui N; Sekiguchi K; Hamaguchi H; Kanda F
    Kobe J Med Sci; 2011 Feb; 56(5):E214-9. PubMed ID: 21937869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.